Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1

Interventions

Azacitidine 62Cyclophosphamide 49fludarabine phosphate 46fludarabine 46Cytarabine 34Decitabine 32venetoclax 27Tacrolimus 21Specimen Handling 21Whole-Body Irradiation 19Mycophenolic Acid 19Melphalan 19Filgrastim 19Busulfan 19Imatinib Mesylate 18ruxolitinib 17Biopsy 15Dasatinib 14Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 13Etoposide 13Clofarabine 13Peripheral Blood Stem Cell Transplantation 12Sirolimus 11Methotrexate 11Ipilimumab 11Injections 11Thiotepa 10Stem Cell Transplantation 10thymoglobulin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Podophyllotoxin × Myeloid × Clear all
NCT01174888 2016-07-06

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
34 enrolled
MyeloidOther hematologic neoplasm

Congenital Abnormalities, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡